| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG2000-Maleimide contains a maleimide group that reacts specifically with thiol groups (-SH) on proteins, peptides, or other thiol-containing molecules to form stable thioether bonds. The DSPE lipid moiety anchors into lipid bilayers, while the PEG spacer provides water solubility and biocompatibility.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG2000-Maleimide is used to prepare liposome-polycation-oligonucleotides complexes for systemic small interfering RNA (siRNA) delivery. The maleimide group enables the conjugation of thiol-containing ligands, such as antibodies or peptides, to liposomes for targeted delivery and surface modification.
|
| ln Vivo |
In vivo, DSPE-PEG2000-Maleimide-containing nanoparticles can be used for targeted drug delivery. The PEG component reduces opsonization and prolongs circulation time, while the maleimide group enables the attachment of targeting moieties for specific delivery to tissues or cells of interest.
|
| Enzyme Assay |
Non-cellular assays for DSPE-PEG2000-Maleimide typically involve demonstrating its ability to react with thiol-containing molecules. The compound can be incubated with a thiol-functionalized molecule, and the formation of the conjugation product can be confirmed by techniques such as mass spectrometry or gel electrophoresis.
|
| Cell Assay |
In vitro cellular assays for DSPE-PEG2000-Maleimide involve treating cells with DSPE-PEG2000-Maleimide-containing nanoparticles to assess their cellular uptake, targeting efficiency, and therapeutic efficacy. The compound itself is a linker and does not have direct biological activity on cells.
|
| Animal Protocol |
In vivo animal experiments for DSPE-PEG2000-Maleimide would involve administering DSPE-PEG2000-Maleimide-containing nanoparticles to animal models to evaluate their biodistribution, pharmacokinetics, and therapeutic efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: DSPE-PEG2000-Maleimide-containing nanoparticles exhibit prolonged circulation due to the PEG component. The pharmacokinetics are influenced by the size, surface properties, and targeting ligands of the nanoparticles. The maleimide group itself does not significantly affect the PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological profile: DSPE-PEG2000-Maleimide is generally considered biocompatible and non-toxic at concentrations used in research applications. PEGylated lipids are well-tolerated, and the maleimide group is not known to be toxic. Standard safety precautions for handling lipid reagents apply.
|
| References |
|
| Additional Infomation |
DSPE-PEG2000-Maleimide has an average molecular weight of 2000 and is a PEGylated phospholipid conjugate. It is used to introduce thiol-reactive functionality onto liposomes and other lipid-based delivery systems. No clinical trial or regulatory approval information is available.
|
| Molecular Weight |
2000 (average)
|
|---|---|
| Related CAS # |
DSPE-PEG-Maleimide (MW 5000);DSPE-PEG2000-Mal ammonium;474922-22-0
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF :~50 mg/mL
DMSO :~12.5 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
